Producing progress? Issues to consider

• Autores: Mara Dierssen Sotos
• Localización: Contributions to Science, ISSN-e 1575-6343, Vol. 10, Nº. 1, 2014, págs. 29-34
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • There is a growing gap in productivity in the biopharmaceutical industry. The money spent on developing new drugs has increased substantially, but the hopedfor dramatic increase in new therapies based on recent revolutions in molecular biology and genetics has yet to materialize. Long approval times, high-failures rates, and high competion account in part for this situation. Some argue that entrepreneurs are not promoting fundamental, new discoveries and instead are simply profiting from the knowledge generated by academia. In fact, publicly funded research is driving progress in a completely new fi eld and the development of a completely new landscape of medicine. The knowledge thereby acquired has dramatically changed the approach to targeting disease. In response, a new model is needed, one that addresses how investment in innovation is driven, but also how innovation is done.